Cambridge, 30th May 2024: Six life science start-ups looking to develop products and services to make a positive difference to healthcare have been selected for one of Europe’s top incubators based at the Babraham Research Campus in Cambridge – Accelerate@Babraham.
The package of support on offer which includes a year’s free lab space, £10k funding and access to an unrivalled network of experts, mentors and investors is always hotly contested and this year was no exception with the selection panel impressed by the strength of extremely high-quality applications.
Introducing the 2024 cohort…
Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) and PrecisionLife, the Causal AI precision medicine company, today announce the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
This is the latest in a series of collaborative agreements between Nxera and PrecisionLife, which began in 2022. The partnership aims to establish new drug targets and subsequently potential precision targeted therapies for auto-immune disorders,…
RNA sequencing is becoming the gold-standard method for uncovering the cellular mechanisms behind disease. A variety of RNA sequencing techniques have evolved, which provide all-important information on disease causes and progression for more effective treatments.
Read our latest blog here:
https://sourcebioscience.com/comparing-rna-sequencing-techniques/
Source LDPath is a flexible and trusted extension to your histopathology laboratory, supporting you to accelerate turnaround times for reporting and decrease backlogs.
In 2023, we successfully reported over 260,000 cases with our NHS histopathology partners, and we are delighted to announce that we have further increased our capacity this year to support your department and provide better patient care.
We have capacity to support:
Pre-prepared Slides
Wet Surgical Specimens
Block to Slide
Wets to Slide
Block to Report
Reporting - Traditional and Digital
Source LDPath provides end-to-end…
We are delighted to announce that our latest whitepaper, written in collaboration with Deloitte: 'Australian R&D Cashback and Early Development Activities', is now available to read and download.
This whitepaper explores the Australian government's initiatives designed to help drug developers swiftly advance their products into early-phase clinical trials, while also benefiting from R&D tax incentives. With streamlined processes, cost efficiencies, a simplified regulatory framework, and a high-quality healthcare sector, Australia is a global competitive destination for…
GMP compliant materials and support for ATMP manufacturing.
AMSBIO is dedicated to helping its customers seamlessly translate their cutting-edge research into production products for clinical therapy. A comprehensive new resource has been added to the website, where you will find links to all the information you need on how AMSBIO can help you better understand and set up a GMP manufacturing process.
In addition to a complete list of GMP compliant products and services, the new section includes an informative ‘Guide to GMP,’ a GMP reference area, and a link to AMSBIO…
Optical genome mapping (OGM) is a workflow that combines various technologies for one purpose: to reveal structural variation in a way that’s never been done before.
Capture and accurately map the entire genome construct, giving a high-resolution view of genome structure with OGM. Structural variations in the form of deletions, duplications, translocations and inversions can be directed imaged, and the analytical gap filled from sequencing technology alone.
Bionano advanced Saphyr imaging instrument
Source Genomics is now able to offer whole genome imaging to visualise structural. Optical…
Source LDPath have further optimised their histopathology courier service to improve on their already market-leading turnaround times. The new and improved courier network has recently launched and will fully replace old courier routes by Monday, May 20th 2024.
Existing clients do not need to do anything and operations will continue as normal.
Samples will travel directly from clinic to laboratory – for a fast and seamless journey via the new courier, Nexus.
These changes will also allow new deliveries to the laboratory on Saturdays for even faster turnaround times.
As a result, there will no…
Asymchem Laboratories (Tianjin) Co., Ltd. announced today that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe. Asymchem will continue to operate the site in Sandwich, Kent, as a clinical small molecule development and manufacturing facility to meet global client demands for pharma services and supply.
The development laboratories are expected to begin operation in June 2024, followed by the API pilot…
We are excited to see that One Nucleus Corporate Patron, AstraZeneca, has announced an ambitious goal to achieve $80 billion in annual revenue by 2030, a significant increase from $45 billion in 2023. This growth will be driven by expanding their oncology, biopharmaceuticals and rare disease portfolios and launching 20 new medicines by the end of the decade. Additionally, AstraZeneca plans to sustain growth beyond 2030 by investing in transformative new technologies. They also committed to halving carbon emissions across their value chain by 2030, demonstrating a dedication to both…